Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence

Author:

Sinicrope Frank A.12ORCID,Nelson Garth D.34ORCID,Saberzadeh-Ardestani Bahar2ORCID,Segovia Diana I.34ORCID,Graham Rondell P.5ORCID,Wu Christina6ORCID,Hagen Catherine E.5ORCID,Shivji Sameer7ORCID,Savage Paul8ORCID,Buchanan Dan D.91011ORCID,Jenkins Mark A.12ORCID,Phipps Amanda I.1314ORCID,Swallow Carol15ORCID,LeMarchand Loic16ORCID,Gallinger Steven17ORCID,Grant Robert C.18ORCID,Pai Reetesh K.19ORCID,Sinicrope Stephen N.20ORCID,Yan Dongyao21ORCID,Shanmugam Kandavel21ORCID,Conner James7ORCID,Cyr David P.15ORCID,Kirsch Richard7ORCID,Banerjee Imon22ORCID,Alberts Steve R.23ORCID,Shi Qian34ORCID,Pai Rish K.24ORCID

Affiliation:

1. 1Departments of Medicine and Oncology, Rochester, Minnesota.

2. 2Gastrointestinal Research Unit, Mayo Clinic, Rochester, Minnesota.

3. 3Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.

4. 4Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.

5. 5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

6. 6Division of Medical Oncology, Mayo Clinic, Phoenix, Arizona.

7. 7Department of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada.

8. 8Mount Sinai Hospital, Toronto, Ontario, Canada.

9. 9Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia.

10. 10University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia.

11. 11Genetic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Victoria, Australia.

12. 12Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.

13. 13Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

14. 14Department of Epidemiology, University of Washington, Seattle, Washington.

15. 15Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada.

16. 16Department of Epidemiology, University of Hawaii, Honolulu, Hawaii.

17. 17Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

18. 18Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

19. 19Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

20. 20University of Chicago Medical Center, Chicago, Illinois.

21. 21Roche Tissue Diagnostics, Tucson, Arizona.

22. 22Department of Radiology and Machine Intelligence in Medicine and Imaging Center (MI-2), Mayo Clinic Arizona, Phoenix, Arizona.

23. 23Department of Oncology, Mayo Clinic, Rochester, Minnesota.

24. 24Department of Pathology and Laboratory Medicine, Mayo Clinic, Arizona.

Abstract

Abstract Deep learning may detect biologically important signals embedded in tumor morphologic features that confer distinct prognoses. Tumor morphologic features were quantified to enhance patient risk stratification within DNA mismatch repair (MMR) groups using deep learning. Using a quantitative segmentation algorithm (QuantCRC) that identifies 15 distinct morphologic features, we analyzed 402 resected stage III colon carcinomas [191 deficient (d)-MMR; 189 proficient (p)-MMR] from participants in a phase III trial of FOLFOX-based adjuvant chemotherapy. Results were validated in an independent cohort (176 d-MMR; 1,094 p-MMR). Association of morphologic features with clinicopathologic variables, MMR, KRAS, BRAFV600E, and time-to-recurrence (TTR) was determined. Multivariable Cox proportional hazards models were developed to predict TTR. Tumor morphologic features differed significantly by MMR status. Cancers with p-MMR had more immature desmoplastic stroma. Tumors with d-MMR had increased inflammatory stroma, epithelial tumor-infiltrating lymphocytes (TIL), high-grade histology, mucin, and signet ring cells. Stromal subtype did not differ by BRAFV600E or KRAS status. In p-MMR tumors, multivariable analysis identified tumor-stroma ratio (TSR) as the strongest feature associated with TTR [HRadj 2.02; 95% confidence interval (CI), 1.14–3.57; P = 0.018; 3-year recurrence: 40.2% vs. 20.4%; Q1 vs. Q2–4]. Among d-MMR tumors, extent of inflammatory stroma (continuous HRadj 0.98; 95% CI, 0.96–0.99; P = 0.028; 3-year recurrence: 13.3% vs. 33.4%, Q4 vs. Q1) and N stage were the most robust prognostically. Association of TSR with TTR was independently validated. In conclusion, QuantCRC can quantify morphologic differences within MMR groups in routine tumor sections to determine their relative contributions to patient prognosis, and may elucidate relevant pathophysiologic mechanisms driving prognosis. Significance: A deep learning algorithm can quantify tumor morphologic features that may reflect underlying mechanisms driving prognosis within MMR groups. TSR was the most robust morphologic feature associated with TTR in p-MMR colon cancers. Extent of inflammatory stroma and N stage were the strongest prognostic features in d-MMR tumors. TIL density was not independently prognostic in either MMR group.

Funder

HHS | NIH | NCI | Center for Cancer Research

Mayo Clinic

Sanofi

Publisher

American Association for Cancer Research (AACR)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3